In a pilot trial, which evaluated subcutaneous versus intra-lymphatic GAD-alum administration in patients with type 1 diabetes, proliferation assays using radiolabeled thymidine showed reduced proliferation to recombinant human GAD65 in those patients given 4 μg GAD-alum intra-lymphatically compared to patients receiving it subcutaneously at 20 μg (70). Here, GAD2 is linked to type 1 diabetes mellitus.